About BioAmber (NYSE:BIOA)
BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company's technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.
Industry, Sector and Symbol
Industry Specialty Chemicals
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$8.27 million
Price / Sales2.84
Price / CashN/A
Book Value$2.05 per share
Price / Book0.22
Return on Equity-48.72%
Return on Assets-22.92%
Frequently Asked Questions for BioAmber (NYSE:BIOA)
What is BioAmber's stock symbol?
BioAmber trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIOA."
How were BioAmber's earnings last quarter?
BioAmber Inc. (NYSE:BIOA) posted its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.27) by $0.02. The biotechnology company earned $2.50 million during the quarter, compared to the consensus estimate of $2.37 million. BioAmber had a negative net margin of 238.43% and a negative return on equity of 48.72%. View BioAmber's Earnings History.
When will BioAmber make its next earnings announcement?
Where is BioAmber's stock going? Where will BioAmber's stock price be in 2017?
2 analysts have issued 12-month target prices for BioAmber's stock. Their forecasts range from $1.00 to $12.00. On average, they expect BioAmber's share price to reach $6.50 in the next year. View Analyst Ratings for BioAmber.
Are investors shorting BioAmber?
BioAmber saw a increase in short interest in October. As of October 31st, there was short interest totalling 4,811,928 shares, an increase of 111.4% from the October 13th total of 2,276,412 shares. Based on an average trading volume of 3,835,155 shares, the short-interest ratio is presently 1.3 days. Approximately 11.3% of the company's stock are sold short.
Who are some of BioAmber's key competitors?
Some companies that are related to BioAmber include Amur Minerals (AMC), TransAtlantic Petroleum Ltd (TNP), McCoy Global (MCB), Beowulf Mining plc (BEM), Canadian Zinc Corp. (CZN), Golden Minerals Company (AUMN), Savannah Resources Plc (SAV), Jubilee Platinum PLC (JLP), Sylvania Platinum Limited (SLP), Clean Diesel Technologies (CDTI), Anglo Asian Mining Plc (AAZ), Marrone Bio Innovations (MBII), Foraco International S.A. (FAR), Rambler Metals and Mining PLC (RMM), Zenyatta Ventures Ltd (ZENYF), Firestone Diamonds PLC (FDI), Plant Health Care plc (PHC) and Eastern Platinum (ELR).
Who are BioAmber's key executives?
BioAmber's management team includes the folowing people:
- Raymond J. Land, Chairman of the Board (Age 72)
- Richard P. Eno, Chief Financial Officer, Director
- Mario Settino, Chief Financial Officer
- Michael A. Hartmann, Executive Vice President (Age 48)
- James Millis, Chief Technology Officer (Age 59)
- Robert Frost, Director
- Kurt W. Briner, Independent Director (Age 70)
- Heinz Haller, Independent Director (Age 62)
- Ellen B. Richstone, Independent Director (Age 65)
- Kenneth W Wall, Independent Director (Age 66)
Who owns BioAmber stock?
BioAmber's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Robecosam AG (2.84%). Company insiders that own BioAmber stock include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Mario Settino and Michael A Hartmann. View Institutional Ownership Trends for BioAmber.
Who bought BioAmber stock? Who is buying BioAmber stock?
BioAmber's stock was acquired by a variety of institutional investors in the last quarter, including Robecosam AG. Company insiders that have bought BioAmber stock in the last two years include George Frederick John Gosbee, Jean-Francois Huc, Kenneth W Wall, Kurt W Briner, Mario Settino and Michael A Hartmann. View Insider Buying and Selling for BioAmber.
How do I buy BioAmber stock?
Shares of BioAmber can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioAmber's stock price today?
One share of BioAmber stock can currently be purchased for approximately $0.45.
How big of a company is BioAmber?
BioAmber has a market capitalization of $22.71 million and generates $8.27 million in revenue each year. The biotechnology company earns $-22,470,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. BioAmber employs 86 workers across the globe.
How can I contact BioAmber?
BioAmber's mailing address is 1250 Rene Levesque West Suite 4310, Montreal A8, H3B 4W8. The biotechnology company can be reached via phone at 514-844-8000 or via email at [email protected]
MarketBeat Community Rating for BioAmber (BIOA)MarketBeat's community ratings are surveys of what our community members think about BioAmber and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for BioAmber (NYSE:BIOA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$6.50 (1,344.44% upside)|
Consensus Price Target History for BioAmber (NYSE:BIOA)
Analysts' Ratings History for BioAmber (NYSE:BIOA)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/10/2017||Cowen and Company||Reiterated Rating||Hold||$1.00||N/A|
|11/8/2017||HC Wainwright||Reiterated Rating||Buy||$12.00||N/A|
|3/13/2017||AltaCorp Capital||Downgrade||Outperform -> Speculative||Medium|
|8/7/2016||Canaccord Genuity||Reiterated Rating||Buy||$5.50||N/A|
|3/28/2016||Credit Suisse Group||Boost Price Target||Outperform||$15.00 -> $17.00||N/A|
|1/5/2016||Rodman & Renshaw||Initiated Coverage||Buy||$18.00||N/A|
Earnings History and Estimates Chart for BioAmber (NYSE:BIOA)
Earnings History by Quarter for BioAmber (NYSE BIOA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/15/2018|| || || || || || || || |
|8/3/2017||6/30/2017||($0.17)||($0.20)||$4.09 million||$4.12 million||View||Listen|
|5/9/2017||3/31/2017||($0.13)||($0.31)||$3.65 million||$2.12 million||View||Listen|
|3/16/2017||12/31/2016||($0.19)||($0.31)||$3.77 million||$0.63 million||View||N/A|
|11/3/2016||Q216||($0.22)||($0.26)||$3.75 million||$3.66 million||View||N/A|
|8/9/2016||Q116||($0.27)||($0.25)||$2.37 million||$2.50 million||View||N/A|
|3/14/2016||Q415||($0.35)||($0.40)||$0.98 million||$1.11 million||View||N/A|
|11/4/2015||Q315||($0.41)||($0.27)||$2.30 million||$0.35 million||View||N/A|
|11/6/2014||Q3 2014||($0.40)||($0.41)||$0.47 million||View||N/A|
|8/7/2014||Q2 2014||($0.40)||$0.40||$0.45 million||$0.42 million||View||N/A|
Earnings Estimates for BioAmber (NYSE:BIOA)
Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.28 EPS
Dividend History for BioAmber (NYSE:BIOA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for BioAmber (NYSE BIOA)
Insider Ownership Percentage: 8.33%
Institutional Ownership Percentage: 44.42%
Insider Trades by Quarter for BioAmber (NYSE BIOA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/18/2017||Michael A Hartmann||Insider||Buy||10,000||$0.48||$4,800.00|| |
|8/9/2017||Mario Settino||CFO||Buy||15,000||$0.53||$7,950.00|| |
|11/9/2016||George Frederick John Gosbee||Director||Buy||25,000||$3.87||$96,750.00|| |
|11/8/2016||Kurt W Briner||Director||Buy||10,000||$3.84||$38,400.00|| |
|5/24/2016||Kurt W Briner||Director||Buy||1,000||$3.69||$3,690.00|| |
|5/23/2016||Kurt W Briner||Director||Buy||21,015||$3.61||$75,864.15|| |
|5/11/2016||Jean-Francois Huc||CEO||Buy||10,000||$3.22||$32,200.00|| |
|5/9/2016||Kenneth W Wall||Director||Buy||13,227||$3.11||$41,135.97|| |
|5/6/2016||Michael A Hartmann||EVP||Buy||3,000||$3.44||$10,320.00|| |
|12/3/2015||Jean-Francois Huc||CEO||Sell||27,278||$8.11||$221,224.58|| |
|12/3/2015||Michael A. Hartmann||EVP||Sell||21,477||$8.11||$174,178.47|| |
|8/14/2015||Michael A Hartmann||EVP||Buy||1,500||$6.75||$10,125.00|| |
|8/11/2015||Jean-Francois Huc||CEO||Buy||4,000||$6.18||$24,720.00|| |
|8/10/2015||Raymond J Land||Director||Buy||1,500||$6.71||$10,065.00|| |
|5/6/2015||Jean-Francois Huc||CEO||Buy||8,800||$9.00||$79,200.00|| |
|5/6/2015||Kurt W Briner||Director||Buy||10,000||$9.00||$90,000.00|| |
|5/6/2015||Michael A Hartmann||EVP||Buy||1,100||$9.00||$9,900.00|| |
|12/11/2014||Kenneth W Wall||Director||Buy||3,000||$9.20||$27,600.00|| |
|12/10/2014||Kenneth W Wall||Director||Buy||5,000||$9.30||$46,500.00|| |
|11/10/2014||Kurt W Briner||Director||Buy||15,000||$9.35||$140,250.00|| |
|9/9/2014||Kurt W Briner||Director||Buy||5,000||$12.00||$60,000.00|| |
|8/25/2014||Kurt W Briner||Director||Buy||14,250||$11.50||$163,875.00|| |
|8/11/2014||Kurt W Briner||Director||Buy||2,980||$11.45||$34,121.00|| |
|7/16/2014||Jean-Francois Huc||CEO||Buy||4,000||$12.00||$48,000.00|| |
|7/16/2014||Michael A Hartmann||EVP||Buy||3,000||$12.00||$36,000.00|| |
|5/12/2014||Andrew P Ashworth||CFO||Buy||3,000||$10.00||$30,000.00|| |
|5/12/2014||Michael A Hartmann||EVP||Buy||2,500||$10.05||$25,125.00|| |
|11/14/2013||Kurt W Briner||Director||Buy||7,200||$6.95||$50,040.00|| |
|9/3/2013||Michael A Hartmann||EVP||Buy||2,000||$4.63||$9,260.00|| |
|8/29/2013||Jean-Francois Huc||CEO||Buy||5,000||$4.25||$21,250.00|| |
|8/15/2013||Kurt W Briner||Director||Buy||13,000||$5.49||$71,370.00|| |
Latest Headlines for BioAmber (NYSE BIOA)
BioAmber (NYSE BIOA) Chart for Thursday, November, 23, 2017